Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine.

No abstract is available for this paper.

• Publication year

  2006

• Venue

  New England Journal of Medicine

• Publication date

  2006-03-30

• Fields of study

  Medicine

• Identifiers
  DOI 10.1056/NEJMOA055778PMID 16571878
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Probable person-to-person transmission of avian influenza A (H5N1).

  2005cited by this paper
• Oseltamivir resistance during treatment of influenza A (H5N1) infection.

  2005cited by this paper
• Immunogenicity of a monovalent, aluminum-adjuvanted influenza whole virus vaccine for pandemic use.

  2004cited by this paper
• Genesis of a highly pathogenic and potentially pandemic H5N1 influenza virus in eastern Asia

  2004cited by this paper
• Avian influenza A (H5N1) in 10 patients in Vietnam.

  2004cited by this paper
• Detection of anti-H5 responses in human sera by HI using horse erythrocytes following MF59-adjuvanted influenza A/Duck/Singapore/97 vaccine.

  2004cited by this paper
• Dose sparing with intradermal injection of influenza vaccine.

  2004cited by this paper
• Serum antibody responses after intradermal vaccination against influenza.

  2004cited by this paper
• Boosting immunity to influenza H5N1 with MF59-adjuvanted H5N3 A/Duck/Singapore/97 vaccine in a primed human population.

  2003cited by this paper
• Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans.

  2001cited by this paper
• Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza.

  2001cited by this paper
• Generation of influenza A viruses entirely from cloned cDNAs.

  1999cited by this paper
• Antibody response in individuals infected with avian influenza A (H5N1) viruses and detection of anti-H5 antibody among household and social contacts.

  1999cited by this paper
• Detection of Antibody to Avian Influenza A (H5N1) Virus in Human Serum by Using a Combination of Serologic Assays

  1999cited by this paper
• Characterization and evaluation of monoclonal antibodies developed for typing influenza A and influenza B viruses

  1986cited by this paper
• Viral respiratory disease at Lowry Air Force Base in Denver, 1952-1982.

  1983cited by this paper
• Live influenza A/Victoria/75 (H3N2) virus vaccines: reactogenicity, immunogenicity, and protection against wild-type virus challenge

  1982cited by this paper
• Protection of infants from infection with influenza A virus by transplacentally acquired antibody.

  1980cited by this paper
• Efficacy of purified influenza subunit vaccines and relation to the major antigenic determinants on the hemagglutinin molecule.

  1979cited by this paper
• Correlated studies of a recombinant influenza-virus vaccine. 3. Protection against experimental influenza in man.

  1971cited by this paper

• Pre-existing neutralizing antibodies against cattle-transmitted influenza A virus H5N1 are detectable in unexposed individuals.

  2026cites this paper
• Safety and immunogenicity of ascending doses of influenza A(H7N9) inactivated vaccine with or without MF59®.

  2025cites this paper
• Immune history shapes human antibody responses to H5N1 influenza viruses

  2025cites this paper
• AVIAN INFLUENZA VIRUS: THE NEXT PANDEMIC?

  2025cites this paper
• Fast and flu-rious: How to prevent and treat emerging influenza A viruses

  2025cites this paper
• Altered germinal center responses in mice vaccinated with highly pathogenic avian influenza A(H5N1) virus.

  2025cites this paper
• Emerging and Pandemic Pathogens: Lessons Learned From a Clinical Research Network.

  2025cites this paper
• A Phylogeny-Informed Mathematical Modeling of H5N1 Transmission Dynamics and Effectiveness of Control Measures

  2025cites this paper
• Vaccine and Treatment Evaluation Units: A Historical Perspective.

  2025cites this paper
• Future Goals and Long-term Vision of the Infectious Diseases Clinical Research Consortium/Vaccine and Treatment Evaluation Unit Network.

  2025cites this paper
• Examining the threat of H5N1 highly pathogenic avian influenza to human health.

  2025cites this paper
• Are we serologically prepared against an avian influenza pandemic and could seasonal flu vaccines help us?

  2024cites this paper
• Basic Properties and Development Status of Aluminum Adjuvants Used for Vaccines

  2024cites this paper
• A Phase 2 Clinical Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of Different Prime-Boost Vaccination Schedules of 2013 and 2017 A(H7N9) Inactivated Influenza Virus Vaccines Administered with and without AS03 Adjuvant in Healthy US Adults.

  2024cites this paper
• Licensed H5N1 vaccines generate cross-neutralizing antibodies against highly pathogenic H5N1 clade 2.3.4.4b influenza virus

  2024cites this paper
• H5N1 Avian Influenza: Global Circulation and Response Strategies

  2024cites this paper
• Avian Influenza Virus A(H5Nx) and Prepandemic Candidate Vaccines: State of the Art

  2024cites this paper
• An influenza mRNA vaccine protects ferrets from lethal infection with highly pathogenic avian influenza A(H5N1) virus.

  2024cites this paper
• Metabolomic Signatures Differentiate Immune Responses in Avian Influenza Vaccine Recipients.

  2024cites this paper
• The practical longevity of stockpiled A(H5N1) influenza vaccine

  2024cites this paper
• Immune history shapes human antibody responses to H5N1 influenza viruses

  2024cites this paper
• Actualización y recomendaciones sobre vacunación antigripal en adultos y niños

  2024cites this paper
• A systemic review on medicinal plants and their bioactive constituents against avian influenza and further confirmation through in-silico analysis

  2023cites this paper
• Influenza virus immune imprinting dictates the clinical outcomes in ferrets challenged with highly pathogenic avian influenza virus H5N1

  2023influential citation
• An Advax-CpG adjuvanted recombinant H5 hemagglutinin vaccine protects mice against lethal influenza infection.

  2023cites this paper
• Prospects for the Use of Metal-Based Nanoparticles as Adjuvants for Local Cancer Immunotherapy

  2023cites this paper
• Immune Control of Avian Influenza Virus Infection and Its Vaccine Development

  2023cites this paper
• Analysis of the safety and immunogenicity profile of an azoximer bromide polymer-adjuvanted subunit influenza vaccine.

  2022cites this paper
• A Review on Equine Influenza from a Human Influenza Perspective

  2022cites this paper
• Safety and immunogenicity of monovalent H7N9 influenza vaccine with AS03 adjuvant given sequentially or simultaneously with a seasonal influenza vaccine: A randomized clinical trial.

  2022cites this paper
• Phase 3 Randomized, Multicenter, Placebo-Controlled Study to Evaluate Safety, Immunogenicity, and Lot-to-Lot Consistency of an Adjuvanted Cell Culture-Derived, H5N1 Subunit Influenza Virus Vaccine in Healthy Adult Subjects

  2022influential citation
• Analysis of the safety and immunogenicity profile of an azoximer bromide polymer-adjuvanted subunit influenza vaccine.

  2022cites this paper
• Vaccine Preparedness for the Next Influenza Pandemic: A Regulatory Perspective

  2022cites this paper
• Recent Progress in Recombinant Influenza Vaccine Development Toward Heterosubtypic Immune Response

  2022cites this paper
• Analysis of the safety and immunogenicity profile of an azoximer bromide polymer-adjuvanted subunit influenza vaccine. [version 1; peer review: awaiting peer review]

  2022cites this paper
• Developments in Vaccine Adjuvants.

  2021cites this paper
• Evaluation of a New Viral Vaccine Vector in Mice and Rhesus Macaques: J Paramyxovirus Expressing Hemagglutinin of Influenza A Virus H5N1

  2021cites this paper
• Study of Antibody-Dependent Reactions of Mast Cells In Vitro and in a Model of Severe Influenza Infection in Mice

  2021cites this paper
• Adjuvanted recombinant hemagglutinin H7 vaccine to highly pathogenic influenza A(H7N9) elicits high and sustained antibody responses in healthy adults

  2021cites this paper
• Polyclonal epitope mapping reveals temporal dynamics and diversity of human antibody responses to H5N1 vaccination

  2021cites this paper
• Topical Imiquimod Does not Provide an Adjuvant Effect when Administered with Inactivated Influenza A/H5N1 Vaccine in Healthy Young Adults.

  2021cites this paper
• Adenoviral Vectors as Vaccines for Emerging Avian Influenza Viruses

  2021cites this paper
• Adjuvanted recombinant hemagglutinin H7 vaccine to highly pathogenic influenza A(H7N9) elicits high and sustained antibody responses in healthy adults

  2021cites this paper
• Hatching Egg Image Segmentation Based on Dense Blocks and the Hierarchical Sampling of Pixels

  2020cites this paper
• Immune Imprinting in the Influenza Ferret Model

  2020cites this paper
• Immunogenicity of H5N1 influenza vaccines in elderly adults: a systematic review and meta-analysis

  2020cites this paper
• Polyclonal epitope cartography reveals the temporal dynamics and diversity of human antibody responses to H5N1 vaccination

  2020cites this paper
• Characterization of thermostable Newcastle disease virus recombinants expressing the hemagglutinin of H5N1 avian influenza virus as bivalent vaccine candidates.

  2020cites this paper
• Human immune responses elicited by an intranasal inactivated H5 influenza vaccine

  2020cites this paper
• It wasn't supposed to be a coronavirus: The quest for an influenza A( H5N1 )‐derived vaccine and the limits of pandemic preparedness

  2020cites this paper
• A conserved multi-epitope-based vaccine designed by targeting hemagglutinin protein of highly pathogenic avian H5 influenza viruses

  2020cites this paper
• Comprehensive Analysis of Antibodies Induced by Vaccination with 4 Kinds of Avian Influenza H5N1 Pre-Pandemic Vaccines

  2020cites this paper
• Mast cell degranulation and histamine release during A/H5N1 influenza infection in influenza-sensitized mice

  2020cites this paper
• Low-dose influenza vaccine Grippol Quadrivalent with adjuvant Polyoxidonium induces a T helper-2 mediated humoral immune response and increases NK cell activity.

  2020cites this paper
• Long-lasting heterologous antibody responses after sequential vaccination with A/Indonesia/5/2005 and A/Vietnam/1203/2004 pre-pandemic influenza A(H5N1) virus vaccines.

  2020cites this paper
• Clinical phase II and III studies of an AS03‐adjuvanted H5N1 influenza vaccine produced in an EB66® cell culture platform

  2020cites this paper
• Adjuvanted H5N1 influenza vaccine enhances both cross-reactive memory B cell and strain-specific naive B cell responses in humans

  2020cites this paper
• Pertinence des méthodes vaccinales actuelles vis-à-vis de l'immunosénescence et nouvelles stratégies développées

  2019cites this paper
• Immune Responses to Avian Influenza Viruses

  2019cites this paper
• Immunity to Influenza: Closing in on a Moving Target

  2019cites this paper
• Human cell-based in vitro systems for vaccine evaluation

  2019cites this paper
• A Phase 2/3 double blinded, randomized, placebo-controlled study in healthy adult participants in Vietnam to examine the safety and immunogenicity of an inactivated whole virion, alum adjuvanted, A(H5N1) influenza vaccine (IVACFLU-A/H5N1).

  2019cites this paper
• Safety and immunogenicity of influenza A(H5N1) vaccine stored up to twelve years in the National Pre-Pandemic Influenza Vaccine Stockpile (NPIVS).

  2019cites this paper
• Influenza A(H5N1) Virus Subunit Vaccine Administered with CaPNP Adjuvant Induce High Virus Neutralization Antibody Titers in Mice

  2019cites this paper
• The safety and immunogenicity of a cell-derived adjuvanted H5N1 vaccine - A phase I randomized clinical trial.

  2019cites this paper
• Effect of recent seasonal influenza vaccination on serum antibody responses to candidate pandemic influenza A/H5N1 vaccines: A meta-analysis.

  2019cites this paper
• Nasal Immunization with a Vaccinia Virus-based Pentavalent H5N1 Avian Influenza Vaccine Induces Cellular Immunity in the Respiratory Tract of Mice

  2019cites this paper
• Heterologous prime-boost with A(H5N1) pandemic influenza vaccines induces broader cross-clade antibody responses than homologous prime-boost

  2019cites this paper
• Safety and immunogenicity of a replication-deficient H5N1 influenza virus vaccine lacking NS1.

  2019cites this paper
• Safety and immunogenicity of an 8 year interval heterologous prime-boost influenza A/H7N7-H7N9 vaccination.

  2019cites this paper
• Recombinant H5 hemagglutinin adjuvanted with nanoemulsion protects ferrets against pathogenic avian influenza virus challenge.

  2019cites this paper
• A live attenuated H5N2 prime- inactivated H5N1 boost vaccination induces influenza virus hemagglutinin stalk specific antibody responses.

  2019cites this paper
• Analysis of the efficacy of an adjuvant-based inactivated pandemic H5N1 influenza virus vaccine

  2019cites this paper
• AS03-Adjuvanted H5N1 Avian Influenza Vaccine Modulates Early Innate Immune Signatures in Human Peripheral Blood Mononuclear Cells

  2018cites this paper
• Atypical antibody responses to influenza.

  2018cites this paper
• CD4 T cells in protection from influenza virus: Viral antigen specificity and functional potential

  2018cites this paper
• AS03-adjuvanted H5N1 vaccine promotes antibody diversity and affinity maturation, NAI titers, cross-clade H5N1 neutralization, but not H1N1 cross-subtype neutralization

  2018cites this paper
• Aluminum salts as an adjuvant for pre-pandemic influenza vaccines: a meta-analysis

  2018cites this paper
• Pandemic influenza vaccines: what they have taught us about B cell immunology.

  2018cites this paper
• 31 – Inactivated Influenza Vaccines

  2018cites this paper
• Opinion: Making Inactivated and Subunit-Based Vaccines Work

  2018cites this paper
• 6 – Evolution of Adjuvants Across the Centuries

  2018cites this paper
• Dose sparing and the lack of a dose–response relationship with an influenza vaccine in adult and elderly patients – a randomized, double‐blind clinical trial

  2017cites this paper
• Developing a platform system for gene delivery: amplifying virus-like particles (AVLP) as an influenza vaccine

  2017cites this paper
• The immune correlates of protection for an avian influenza H5N1 vaccine in the ferret model using oil-in-water adjuvants

  2017cites this paper
• Safety and effectiveness assessment of 2011–2012 seasonal influenza vaccine produced in China: a randomized trial

  2017cites this paper
• H5N1 influenza vaccine induces a less robust neutralizing antibody response than seasonal trivalent and H7N9 influenza vaccines

  2017cites this paper
• Addition of αGal HyperAcute™ technology to recombinant avian influenza vaccines induces strong low-dose antibody responses

  2017cites this paper
• A Formulated TLR7/8 Agonist is a Flexible, Highly Potent and Effective Adjuvant for Pandemic Influenza Vaccines

  2017cites this paper
• Proteomics show antigen presentation processes in human immune cells after AS03‐H5N1 vaccination

  2017cites this paper
• Cell-Based Systems Biology Analysis of Human AS03-Adjuvanted H5N1 Avian Influenza Vaccine Responses: A Phase I Randomized Controlled Trial

  2017cites this paper
• Avian and Human Seasonal Influenza Hemagglutinin Proteins Elicit CD4 T Cell Responses That Are Comparable in Epitope Abundance and Diversity

  2017cites this paper
• Influenza vaccines manufacturing in continuous cell lines: problems and solutions

  2017cites this paper
• Stable emulsion (SE) alone is an effective adjuvant for a recombinant, baculovirus-expressed H5 influenza vaccine in healthy adults: A Phase 2 trial.

  2017cites this paper
• Fighting against a protean enemy: immunosenescence, vaccines, and healthy aging

  2017cites this paper
• Vaccines in the Prevention of Viral Pneumonia.

  2017cites this paper
• Vaccine With MF59 Adjuvant A Randomized Clinical Trial

  2017cites this paper
• Poly-γ-glutamic acid/chitosan nanogel greatly enhances the efficacy and heterosubtypic cross-reactivity of H1N1 pandemic influenza vaccine

  2017cites this paper
• A humanized mouse model identifies key amino acids for low immunogenicity of H7N9 vaccines

  2017cites this paper
• Cross-Reactive Antibody Responses to Novel H5Nx Influenza Viruses Following Homologous and Heterologous Prime-Boost Vaccination with a Prepandemic Stockpiled A(H5N1) Vaccine in Humans

  2017cites this paper